← Human Trials & Peer-Reviewed Studies
PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
Plain-language guide to PMID 17379359 (2008): double-blind randomized controlled trial of Therapeutic nicotine (patch, non-peptide) in 18 patients.
Key Facts
- PMID
- 17379359
- Journal
- Neurobiology of aging
- Year
- 2008
- Study type
- Randomized Controlled Trial
- Authors
- Kadir A et al. (11 authors)
- DOI
- 10.1016/j.neurobiolaging.2007.02.020
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
The effect of galantamine treatment on cortical acetylcholinesterase (AChE) activity and nicotinic receptor binding was investigated by positron emission tomography (PET) in 18 patients with mild Alzheimer's disease (AD) in relation to galantamine concentration and the patients' cognitive performances.
The patients underwent PET examinations to measure cortical AChE activity ((11)C-PMP) and (11)C-nicotine binding.
Who Took Part
The study group was 18 patients.
PubMed indexes the participants as older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.
Some patients received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.
What Was Measured
The patients underwent PET examinations to measure cortical AChE activity ((11)C-PMP) and (11)C-nicotine binding.
Neuropsychological tests were performed throughout the study.
PubMed files the paper under topics including Acetylcholinesterase, Alzheimer Disease, Brain, Cholinesterase Inhibitors, Enzyme Activation, Galantamine and Nicotine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide) in 18 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2008 (Neurobiology of aging), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.